This is particularly relevant as the selective expression of tumor associated antigens that originally facilitated development of therapeutic antibodies for lymphoma, HER2+ breast cancer and neuroblastoma, are the ideal targets for next generation CAR-T and CAR-NK therapies where both direct recognition and ADCC could synergise for optimal outcome. This evidence concerns the gene ERBB2 and breast carcinoma.